

12th World AIDS Conference

Updated Programme: 1 June, 1998

Please note : This document is supplementary to the Advance Program found in the Conference Workbook. All sessions are subject to cancellation or rescheduling up to the date of the Conference.



Monday, June 29

Overwhelmed ?

Please visit the Itinerary Builder Program available at <http://www.aids98.ch>

Venue: **Arena**
PL1 Plenary Session: Prevention **9:00 - 10:30**
Chair 1: **Dreifuss, Ruth**
Chair 2: **Augustine-Sah, Gunjan**

1	HIV vaccines <i>Wigzell</i>	
2	Mother-to-child HIV transmission <i>Mofenson</i>	
3	Mother-to-child HIV transmission <i>Makhalemele</i>	
4	"Preventing HIV in new generations: expanding the successes; understanding the failures" <i>Sittitrai</i>	

Venue: **Hall III** **11:00 - 12:30**
A11 Regulation of HIV Replication
Chair 1: **Felber, Barbara**
Chair 2: **Hosein, Sean**
Time

5	HIV transcription <i>Jones</i>	
6	NEF <i>Trono</i>	
7	Late events including protease <i>Swanstrom</i>	

Venue: **Hall IV** **11:00 - 12:30**
A12 Chemokines and Receptors I
Chair 1: **Levy, Jay A.**
Chair 2:

	CD+ cell antiviral factors: clinical relevance <i>Levy</i>	
8	Adaptation to promiscuous usage of CC and CXC chemokine co-receptors in vivo correlates with HIV-1 disease progression <i>Lal</i>	21134
9	Chemokine receptor usage of HIV-1 primary isolates of different genetic subtypes <i>Tscherning</i>	11166
10	Co-receptors and cellular targets for HIV-1 in the human female genital tract <i>Hladik</i>	11106
11	CCR5 genotype may confer resistance to mother-to-child HIV-1 transmission <i>Philpot</i>	21107
12	Host's genetic background of HIV-1 infected long-term nonprogressors in France <i>Magjerowska</i>	13346
13	Th1 and Th2 Lymphocytes are permissive for CCR5-, but not for CXCR4-dependent HIV <i>Poli</i>	21147

Venue: **Hall VII** **11:00 - 12:30**
B11 Cytomegalovirus and Hepatitis-C Virus
Chair 1: **Oka, Shinichi**
Chair 2: **Trepo, Christian**

14	Sustained disappearance of human cytomegalovirus (HCMV) in blood of AIDS patients following HAART. <i>Gerna</i>	22237
15	Evidence that HAART induced immune recovery vitritis in CMV retinitis patients is immune mediated <i>Torriani</i>	22240
16	Recurrence of CMV disease in patients with a history of CMV retinitis receiving protease inhibitors <i>Costagliola</i>	22239
17	Rapidly evolving hepatitis-C virus infection in HIV coinfectd patients treated with HAART <i>Pialoux</i>	22243
18	Lack of effect of long-term HAART on hepatitis C (HCV) viremia <i>Rutschmann</i>	22238

19	The correlation between HIV and hepatitis-C co-infection: A case control study <i>Hoffman-Terry</i>	22255
20	Long-term response to interferon therapy in HIV-infected patients with chronic hepatitis C <i>Garcia-Samaniego</i>	22242

Venue: **Arena** **11:00 - 12:30**
B12 Antiretroviral Therapy: Issues in Clinical Management
Chair 1: **Benson, Constance A.**
Chair 2: **Whittaker, Bill**

21	Initiation of therapy <i>Vella</i>	
22	Monitoring therapy <i>Richman</i>	
23	Long-term management: maintenance and salvage <i>Yeni</i>	

Venue: **Hall V** **11:00 - 12:30**
C11 Gay Men: Risks and Community Response
Chair 1: **Hernandez, Juan Jacobo**
Chair 2: **Speith, Jovesa**

24	Social-normative factors partially explain the association between younger age and HIV risk in gay/bisexual men in the U.S. <i>Mansergh</i>	23349
25	Are youth and drug use risk factors among German gay men? <i>Bochow</i>	23105
26	Study of dangerous behavioural patterns in teenage boy sex workers and their clients in St.Petersburg <i>Scherbakov</i>	23133
27	Negotiated safety and agreements between men in relationships: Are all agreements equal? <i>Crawford</i>	23132
28	Differential effects of multiple loss on safe sex intentions and behaviour in gay men <i>Sandfort</i>	14258
29	HIV prevention for clients of male sex workers: An experiment in planned action <i>Zuilhof</i>	43367

Venue: **Hall VI** **11:00 - 12:30**
C12 Mother-to-Child HIV Transmission: Latest Research
Chair 1: **Dennison, Rebecca**
Chair 2: **McIntyre, James A.**

30	Randomised placebo-controlled trial of short-course oral ZDV to reduce perinatal HIV-transmission, Thailand <i>Shaffer</i>	33163
31	Study drug adherence and tolerance within a randomised clinical trial to evaluate a short-course regimen of zidovudine to reduce mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire <i>Ekpini</i>	23280
32	Petra study <i>Late breaker</i>	
33	Vitamin A <i>Late breaker</i>	
34	Other <i>Late breaker</i>	
35	Placebo control trials of short-course Antiretroviral regimens to reduce mother-to-child HIV transmission are essential to establish standard of care in Africa <i>Kahn</i>	42201

Oral Sessions Programme

Monday, June 29

Venue: Satellite 2000
C13 **Prevention Programmes for Youth** **11:00** - **12:30**
Chair 1: Satcher, David
Chair 2: Kilrya, Stephen

36	Sex education and HIV/STD prevention program for adolescents <i>Pinto Costa</i>	13498
37	Evaluation results from the Safer Choices project: A multifaceted HIV prevention intervention program for high school students <i>Banspach</i>	14249
38	Multicultural peer group project creates effective AIDS awareness <i>Greyling</i>	33517
39	Sexual health in a young city: a community-based intervention on youth sexual health in Lima <i>Caceres</i>	43170
40	Evaluation of a brief general practice-based intervention to reduce STD (sexually transmitted disease) risk behaviour among adults aged 18-25 years <i>Proude</i>	14253
41	Baseline evaluation of a school-based peer education programme in Zimbabwe <i>Woelk</i>	33518
42	Lessons for health policy in the US <i>Satcher</i>	

Venue: Hall I
D11 **End of Life Issues** **11:00** - **12:30**
Chair 1: Van den Boom, Frans
Chair 2: Deschenes, Suzan

43	AIDS and euthanasia: old problems, new issues <i>Starace</i>	24244
44	"End of life issues - "The Road to Geneva" <i>Campbell</i>	22438
45	Morphine as a euthanatic: Subjective experiences from care providers <i>Ogden</i>	24247
46	Euthanasia: The opinion of Europeans with HIV-infection <i>Fleerackers</i>	22426
47	Picking up the pieces: Caregivers of adolescents bereaved by parental AIDS <i>Rotheram-Borus</i>	44215
48	What will happen to my children? Planning for children before death with single mothers in the Slums of Nairobi <i>Philips</i>	34187

Venue: Hall II
D12 **Policy and Programme Evaluation: Does it Matter?** **11:00** - **12:30**
Chair 1: Tarantola, Daniel
Chair 2: Dubois-Arber, Françoise

49	Evaluation of national AIDS prevention in Senegal <i>Ndoye & Carael</i>	
50	Evaluation of national AIDS prevention in the USA <i>Holtgrave & Rugg</i>	
51	Evaluation of the national AIDS prevention strategy in Switzerland <i>Zeltner & Spencer</i>	
52	Discussant <i>Sarkar</i>	
53	Discussant <i>Child</i>	

Venue: Hall IV
A13 **Chemokines and Receptors II** **13:00** - **14:30**
Chair 1: Paxton, William
Chair 2: Kokeny, Mihaly

54	Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by CCR5D32 <i>Jiang</i>	11105
55	Induction of phosphorylation and association of CC chemokine receptor 5 and focal adhesion kinase in CD4+T cells by macrophage-tropic HIV envelope <i>Cicala</i>	21135
56	Modulation of HIV-1 infection by CCR5 antagonists <i>Mosier</i>	11103
57	Bicyclams are selective antagonists of the chemokine receptor CXCR4 and potent inhibitors of HIV <i>Schols</i>	11107

58	AOP-RANTES inhibits CCR5 recycling - A novel inhibitory mechanism of HIV infectivity <i>Proudfoot</i>	11102
59	Efficacy of aminooxypentane (AOP)-RANTES as inhibitor of HIV-1 infectivity without impairment of cellular proliferation <i>Rusconi</i>	41231

Venue: Hall III
B13 **Nursing Care** **13:00** - **14:30**
Chair 1: MacNeil, Joan
Chair 2: Tlou, Sheila

60	Ambulatory nursing care for HIV positive patients in treatment for tuberculosis <i>Sin Koc</i>	22467
61	HIV/Tuberculosis (TB) liaison nurse in the HIV clinic <i>Otaya</i>	13247
62	Nursing care for persons with and without HIV infection at the University Hospital Antwerp: Compliance with universal precautions <i>Veerle</i>	new name 22459
63	Degree of comfort in providing care to clients with HIV disease: A study of nurses in Ho Chi Minh City, Vietnam <i>Correll</i>	22464
64	Humour in AIDS nursing care is no taboo! <i>Lenzin, Patrick</i>	new name 22485
65	Adherence barriers to complex antiretroviral regimen: The perceptions of HIV+ women and nurses <i>Kosko</i>	32352
66	Effect of supportive nursing care on life satisfaction and self-care ability in HIV infected persons <i>Sangkard</i>	22460
67	Home care for people living with AIDS in Bangkok - Involving families and optimising the use of hospital resources <i>Wilson</i>	22442

Venue: Hall VII
B14 **Care in Resource-Limited Settings** **13:00** - **14:30**
Chair 1: Ottenweller, Marc
Chair 2: Were, Beatrice Nabwire

68	The changing impact of HIV/AIDS in Kenyatta National Hospital (KNH), Nairobi, Kenya, from 1988/89 through 1992 to 1997. <i>Arthur</i>	42434
69	Affordable medical care for HIV/AIDS patients to control opportunistic infections <i>Ngugi</i>	42425
70	"Comprehensive care across a continuum: Uganda experience" <i>Bakyaita</i>	12411
71	Clinical profile of 1800 HW/AIDS patients at the only comprehensive AIDS clinic in Bombay - India <i>Bodhare</i>	12409
72	Evolution of primary health care concepts in community responses to HIV/AIDS in a Northern Thai HIV epicentre <i>Silarug</i>	42398
73	Care in resource-limited settings <i>Neprom</i>	12410
74	The impact of family support on outcome of hospitalisation for symptomatic HIV infection <i>Bruinsma-Adams</i>	12412
75	Care and treatment: increased access at low cost in Burkina Faso <i>Sawadogo</i>	12405

Venue: Arena
B15 **Opportunistic Infections** **13:00** - **14:30**
Chair 1: Clumeck, Nathan
Chair 2: Houyez, François

76	Opportunistic infections in the era of HAART <i>Egger</i>	
77	Opportunistic infections and care in developing countries <i>Sirisanthana</i>	
78	Prophylaxis of opportunistic infections <i>Currier</i>	

Oral Sessions Programme

Monday, June 29

Venue:	Hall V			
C14	Access to Diagnosis and Treatment Accessible	13:00	-	14:30
Chair 1:	Ngugi, Elizabeth			
Chair 2:	Holmes, King			
79	Sensitivity and specificity of syndromic diagnosis of some STDs among sex workers in Bali, Indonesia <i>Wirawan</i>			33235
80	The value of risk assessment in the detection of gonococcal/chlamydial cervical infections at a Ugandan STD clinic <i>Tumwesigye</i>			33230
81	Women personal collection of specimens as an alternate strategy in fighting STD without speculum <i>Flichman</i>			22193
82	Progress in STD diagnostics <i>Schachter</i>			
83	Integrated reproductive health services improve clients' particularity women's access to STD treatment in Nepal <i>Karki</i>			33237
84	Increasing antibiotic resistance in gonococci in the WHO Western Pacific Region (WPRO) <i>Poumerol</i>			33231
Venue:	Hall VI			
C15	Bridging Session: Mother-to-Child HIV. Transmission: Research Into Policy and Practice	13:00	-	14:30
Chair 1:	Bianco, Mabel Beatriz			
Chair 2:	Saba, Joseph			
85	Relevance of current trials to breast-feeding policy and practice <i>van de Perre</i>			
86	Operationalizing trial results in an African district <i>Wilkinson</i>			
87	Challenges to the pharmaceutical industry <i>Repres. of Pharmaceutical</i>			
88	Ethical issues <i>Odhiambo</i>			
89	Discussant: Programmes at country level <i>de Vincenzi</i>			
90	Discussant <i>Moses</i>			
91	Discussant <i>Amman</i>			
Venue:	Satellite 2000			
C16	Sociocultural & Behavioural Determinants of HIV Transmission	13:00	-	14:30
Chair 1:	Horton, Meurig Iestyn			
Chair 2:	Lamprey, Peter			
92	"Constructs of "community" in HIV/AIDS health promotion in Australia" <i>Dowsett</i>			34186
93	HIV/AIDS and men who have sex with men in the South Pacific: a partnership between a marginalised group, a CBO and a regional university <i>Speith</i>			43380
94	Inequalities in declining HIV-related mortality - Chicago, Illinois, USA - 1996 <i>Whitman</i>			43433
95	Cross-border migrations and HIV/AIDS transmission in Myanmar's Golden Triangle <i>Desbarats</i>			24116
96	Love magic and HIV risk in Papua New Guinea <i>Jenkins</i>			14318
				abstract withdrawn
Venue:	Hall I			
D13	Male Sexuality	13:00	-	14:30
Chair 1:	Almedal, Calle			
Chair 2:	Jenkins, Carole			
97	Overview (the male)(sociological approach) <i>Segal</i>			
98	Men, sex and HIV anthropological approach <i>Welzerlang</i>			
99	Men, men and sex <i>Oetomo</i>			
100	Men practising sex <i>Petzer</i>			
101	Discussant <i>Altman</i>			

Venue:	Hall II			
D14	Overcoming Obstacles to Action	13:00	-	14:30
Chair 1:	Ragi, Allan			
Chair 2:	Borromeo, Elena			
103	A national awareness campaign in a country where silence rules <i>Reyna Ganteaume</i>			34217
104	Influencing government policy in Israel: a case study in activism <i>Hassman</i>			44257
105	HIV/AIDS prevention and control through creation of awareness by motivating and mobilising religious leaders <i>Mahmud</i>			34101
106	The Afro-Brazilian religions and the reduction of risk of HIV/AIDS infection <i>Mott</i>			14215
107	HIV infection impact among North African people living in France: actions and survey to promote prevention and better access to care <i>Imane</i>			33256
108	The role of appropriate policies in the fight against HIV/AIDS: Uganda's experiences and the way forward <i>Nsubuga</i>			34309
Venue:	Hall III			
A14	Immune Reconstitution Following HAART	15:00	-	17:00
Chair 1:	Clerici, Mario			
Chair 2:	Van Lunzen, Jan			
109	Initiation of antiretroviral therapy during primary HIV infection is associated with rapid stabilisation of the TCR V Beta repertoire and reduction of CD8+ T cell oligoclonality <i>Soudeyns</i>			31121
110	Down regulation of CD8+ T cell expansions in HIV patients receiving highly active combination therapy <i>Gorochoy</i>			31165
111	Specific T-cell responses in HIV-infected patients after highly active antiretroviral treatment (HAART) <i>Leandersson</i>			31142
112	Prolonged suppression of HIV-1 viremia results in profound but incomplete enhancement of anti-HIV-1 CTLm responses in advanced infection <i>Rinaldo</i>			31124
113	Functional lymphocyte reconstitution and HIV-1 specific T cell responses during highly active antiretroviral therapy (HAART). <i>Pontesilli</i>			31134
114	Immune reconstitution and role of thymus during potent antiretroviral therapy in vertically HIV-infected children <i>Vigano</i>			12247
115	Improved cellular immunity in acute HIV-1 infection following antiretroviral therapy <i>Mcelrath</i>			31177
116	Expression of CD28 and CD38 by CD8+ T cells in HIV infection correlates with viral load and CD4+ T cell number at baseline and during treatment <i>Burgisser</i>			31170
Venue:	Hall IV			
A15	Early Events in HIV Cycle	15:00	-	17:00
Chair 1:	Pavlikis, George			
Chair 2:				
117	Chemokines and chemokine receptors in HIV infection <i>Lusso</i>			
118	HIV co-receptors <i>Berger</i>			
119	Nuclear transport and pre-integration complex <i>Stevenson</i>			
120	The HIV nucleocapsid protein as a molecular chaperone and drug target in the viral life cycle <i>Darlix</i>			
Venue:	Hall VII			
B16	Bridging Session: Nursing Care. Building Bridges from Hospital to Home	15:00	-	17:00
Chair 1:	Anderson, Sandra			
Chair 2:	Ghebrehiwet, Tesfamicael			
121	Nursing contributions in a military setting <i>Putia</i>			

Oral Sessions Programme

Monday, June 29

122	The Starting Point of Home Care for AIDS Patients in Japan <i>Ishihara, Miwa</i>	new name and title
123	University outreach for community-based care <i>Nantachaijapun</i>	
124	Focus on children from home to hospital <i>Boland</i>	

Venue: B17
Chair 1: Hirsch, Martin
Chair 2: Cox, Spencer
ART I: Clinical Trials **15:00 - 17:00**

125	ACTG 364: virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFV) in combination with new nucleoside analogs in nucleoside experienced subjects <i>Albrecht</i>	12203
126	Saquinavir/ ritonavir may have better antiviral efficacy than either ritonavir or indinavir in HIV infected antiretroviral naive patients <i>Pedersen</i>	12221
127	Safety and activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral naive subjects <i>Fischl</i>	12230
128	Antiretroviral activity and safety of abacavir (1592, ABC) with 3TC/ZDV in therapy-experienced children <i>Van Dyke</i>	12255
129	Interim analysis of plasma viral burden reductions and CD4 increases in HIV-1 In patients with Rescriptor (DLV) + Retrovir (ZDV) + Eпивir (3TC) <i>Wathen</i>	12219
130	A phase II, multicenter, randomised, open-label study to compare the antiretroviral activity and tolerability of Efavirenz (EFV) + Indinavir (IDV), versus EFV + Zidovudine (ZDV) + Lamivudine (3TC), versus IDV + ZDV + 3TC at 24 weeks [DMP 266-006] <i>Staszewski</i>	22236
131	An effectiveness trial comparing AZT/ddl to AZT/ddC in Thailand <i>Satasit</i>	42244
132	A multicenter randomised study comparing ritonavir and indinavir in 1251 previously treated patients with CD4 below 50/mm3. (Italian ISS-IPI Study Group) <i>Vella</i>	12237

Venue: C17
Chair 1: Nguyen Van Doan
Chair 2: Miller, David
Hall V
Counselling and Testing **15:00 - 17:00**

133	Voluntary HIV Counselling & Testing (VCT) reduces risk behaviour in developing countries: Results from the voluntary counselling and testing study <i>Coates</i>	33269
134	Client's views on HIV counselling and testing - Is it helpful? <i>Kayawe</i>	33265
135	Performance of a rapid HIV testing algorithm for same day results at the AIDS Information Centre, Uganda <i>Mujurizi</i>	43109
136	HIV testing behaviour among at-risk populations: Why do persons seek, defer, or avoid getting tested in the United States? <i>Lehman</i>	43103
137	Unawareness of HIV seropositivity before AIDS diagnosis in Europe <i>Hamers</i>	43105
138	Which Individuals undergo Voluntary HIV serologic Testing in Puerto Rico? <i>Albizu</i>	43121
139	Unlinked and anonymous counselling to the general public through an interactive Voice Response System (IVRS) <i>Chandhok</i>	33473

Venue: C18
Chair 1: Binder, Louise
Chair 2: Ignacio, Johannes
Hall VI
Bridging Session: Human Rights and Public Health **15:00 - 17:00**

140	Overview <i>Gruskin</i>
141	Balancing confidentiality and care delivery <i>Lucas</i>

142	Criminalisation of HIV transmission <i>Kanyangarara</i>
143	Increased vulnerability in countries in economic transition <i>Pyoryshkina</i>
144	Right to information / civil rights <i>Valencio-Palacios</i>
145	Discussant <i>Cameron</i>

Venue: D15
Chair 1: Bertozzi, Stefano
Chair 2: Lucas, Sue
Hall I
Politics Behind HIV/AIDS Policies **15:00 - 17:00**

146	Politics of HIV/AIDS prevention: appropriate approaches, fostering and impeding factors <i>Rosenbrock</i>
147	The case of South Africa <i>Schneider</i>
148	The case of Russia <i>Chervyakov</i>
149	The case of India <i>Ramasubban</i>
150	Discussant <i>Ballard</i>

Venue: D16
Chair 1: Ikegami, Chizuko
Chair 2: Youth from Opening Ceremony
Hall II
Youth & Vulnerability **15:00 - 17:00**

151	Introduction <i>McCaughey</i>	
152	HIV/AIDS, risk perception and adolescents in Lima, Peru <i>Quintana</i>	14210
153	Risk perception and condom use among adolescents during summer vacations <i>Cavalheiro</i>	14264
154	Self-acceptance of gay identity decreases sexual risk behaviour and increases psychological health in U.S. young gay men <i>Waldo</i>	14135
155	Varieties of homosexuality in Bangladesh: Implications for HIV prevention <i>Jenkins</i>	14312
156	Mother-daughter communication: A two way process <i>Nzegwu</i>	34347

Notes

Oral Sessions Programme

Tuesday, June 30

Venue:	Arena			
PL2	Plenary Session:	9:00	-	10:30
	The Virus: Pathogenesis, Reservoirs and Spread			
Chair 1:	Montagnier, Luc			
Chair 2:	Neal, Leigh			

157	From new knowledge about the virus and pathogenesis to better treatment: host s for therapy <i>Fauci</i>		
158	Cure: myth or reality? Latent reservoirs for HIV <i>Siliciano</i>		
159	Cure: myth or reality? <i>Harrington</i>		
160	Epidemiology of HIV infection: new and emerging epidemics <i>Abdool Karim</i>		

Venue:	Hall IV			
A21	Viral Assays and Diagnostics	11:00	-	12:30
Chair 1:	Mhalu, Fred S			
Chair 2:	Chieco-Bianchi, Luigi			

161	Determination of HIV-1 subtypes using dried blood spots (DBS) and V3 peptide serotyping in Thailand <i>de Souza</i>	42101	
162	Interactions of secretory IgA with HIV-1 gp120: potential pitfalls of anti-HIV ELISA using Saliva <i>Jackson</i>	41101	
163	HIV-screening with the Elecsys® automated analyser: Combined Testing for anti-HIV and HIVAg within 18 minutes <i>Donié</i>	41102	
164	Plasma and genital tract viral load and STDs in early HIV infection <i>Celum</i>	42141	
165	A community-based study of HIV-2 RNA load in pregnant women attending health centres, in West Africa <i>Ngom</i>	41135	
166	RNA and DNA PCR for early diagnosis of infants born to HIV-infected mothers, Thailand <i>Young</i>	42106	

Venue:	Arena			
A22	Viral and Cellular Dynamics	11:00	-	12:30
Chair 1:	Everitt, Dawn			
Chair 2:	Neumann, Avidan			

167	Turnover of HIV <i>Ho</i>		
168	Lymphocyte dynamics and mechanisms of CD4 <i>Miedema</i>		
169	Viral evolution <i>Wain-Hobson</i>		

Venue:	Hall III			
B21	Paediatric Care and Treatment	11:00	-	12:30
Chair 1:	Della Negra, Marinella			
Chair 2:	Tudor-Williams, Gareth			

170	Vitamin A supplements and mortality among HIV positive and negative children in Tanzania <i>Fawzi</i>	42331	
171	Implementation of recommendations for the medical care of HIV-exposed infants in the first year of life, U.S.A <i>Bertolli</i>	23269	
172	The impact of HIV infection on in-hospital paediatric mortality at Chris Hani Baragwanath Hospital (CHBH), South Africa <i>Meyers</i>	new name	12166
173	First large US study of efficacy and tolerability of ritonavir in HIV-infected children <i>Pelton</i>		12246
174	How often can signs, symptoms and immunological abnormalities predict perinatal HIV infection in Brazilian infants? <i>Mussi-Pinhata</i>		12169
175	Ageing cohort of perinatally HIV-infected children in New York City (NYC) <i>Thomas</i>		13363
12'171	Heart, lung and immune abnormalities and high viral burden in rapid paediatric HIV-1 disease <i>Shearer</i>		

Venue:	Hall VII			
B22	Complications of Protease Inhibitors	11:00	-	12:30
Chair 1:	Gatell, José			
Chair 2:	Seligmann, Maxime G.			

176	Introduction <i>Cooper</i>		
177	Changes in body habitus in HIV (+) women after initiation of protease inhibitor therapy <i>Dong</i>	12373	
178	Metabolic changes in HIV-infected patients treated with protease inhibitors <i>Bernasconi</i>	12375	
179	Peripheral insulin resistance leading to impaired glucose tolerance in HIV-1 infected patients treated with protease inhibitors <i>Walli</i>	41177	
180	Discontinuation (D/C) of protease inhibitor (PI) therapy: reasons and risk factors <i>Hirschhorn</i>	12443	

Venue:	Hall V			
C21	Commercial Sex: Male Clients and Female Workers	11:00	-	12:30
Chair 1:	Piwo, Joanne			
Chair 2:	Overs, Cheryl			

181	Invited speaker: Issues and priorities in Latin America <i>Pernia</i>		
182	Decline in prevalence of HIV infection and sexually transmitted diseases and increase in condom use among female sex workers in Abidjan, Côte d'Ivoire, 1992-1997 <i>Diallo</i>	43236	
183	Peer education/awareness among commercial sex worker in Pokhara, <i>Bista</i>	23508	
184	Promoting condom use among female sex workers in natural settings in Yunnan, China <i>Wu</i>	33332	
185	Criteria for evaluation of education given to clients of sex workers <i>Van Mens</i>	43229	
186	Scaling up of interventions through community-based organisations <i>Chowdhury</i>	34210	

Venue:	Hall VI			
C22	Treatment Impact, Biological Factors and Disease Progression	11:00	-	12:30
Chair 1:	Schechter, Martin			
Chair 2:	Mboya, Tom			

187	Long term survivors under observed effectiveness of highly active antiretroviral therapy <i>Munoz</i>	13349	
188	Estimating the effect of treatments on AIDS incidence in Australia <i>Kaldor</i>	43477	
189	Survival following HIV seroconversion evidence of a recent change? <i>Porter</i>	13335	
190	Long-term nonprogressors (LTNP): Prevalence and predictors through 18 years of follow-up <i>Vittinghoff</i>	13347	
191	Viral load and CD4 cell count in Injecting Drug Users (IDUs) newly infected with HIV-1 subtypes B and E, Bangkok <i>Mastro</i>	13302	
192	Geographic variation in disease progression in 664 HIV-1 seroconverted injecting drug users in Europe? <i>Prins</i>	13338	

Venue:	Satellite 2000			
C23	New Developments in Public Health Surveillance	11:00	-	12:30
Chair 1:	Baker, Cornelius			
Chair 2:	Klavs, Irena			

193	Broadening the tools for public health surveillance – a wider range of indicators <i>Schwartländer</i>		
194	Ongoing changes in surveillance systems in Europe including Eastern Europe <i>Infuso</i>		
195	Moving to national HIV reporting (USA) <i>Gostin</i>		
196	Population-based versus sentinel site surveys in Zambia <i>Musonda</i> Discussant <i>Bayer</i>		

Oral Sessions Programme

Tuesday, June 30

Venue:	Hall I			
D21	Implications of Therapies for Developing Countries	11:00	-	12:30
Chair 1:	Pedraza, Jairo			
Chair 2:	Guerma, Teguest			
197	Introduction & overview <i>Coll-Seck</i>			
198	NGO networking for access to drugs in West Africa (review of sub-regional initiatives) <i>Sylla</i>			
199	Investigation of access to HIV-related treatments in Asia through NGO collaborations <i>Merati</i>		34141	
200	Government perspective on access to care in Brazil and Latin America <i>Chequer</i>			
201	A cross country perspective <i>Over</i>			
202	Implication of the private sector: access to care for employees <i>Cheevers declines</i>			

Venue:	Hall II			
D22	Gender and Power	11:00	-	12:30
Chair 1:	Cannings, Dusilley			
Chair 2:	Apisuk, Chumpon			
203	Reducing gender-related barriers in HIV prevention efforts: Findings from ICRW's Women and AIDS Research Program <i>Weiss</i>		14262	
204	Gender Issues in HIV Prevention for Heterosexual Men <i>Esher</i>		43381	
205	Cultural beliefs: barriers to sex discussion among married couples and its implications in STD/HIV/AIDS prevention in Malawi <i>Chaima</i>		14213	
206	"Gender and STD/HIV risk in nine populations in Nepal: challenging the ideal of a woman of ""good character"" <i>Malla Shrestha</i>		14227	
207	Power echoes: The impact of gendered power relations on HIV/AIDS risk and risk reduction as echoed in survey responses <i>Swezey</i>		14182	
208	Whose turn tonight? An appropriation of the circumstances of condom use (purchase, proposal, donning) by gender <i>Spencer</i>		33103	

Venue:	Hall III			
A23	Mother-to-Child HIV Transmission: Biological Determinants	13:00	-	14:30
Chair 1:	Coovadia, Hoosen			
Chair 2:				
209	Viral dynamics in neonatal macaques after oral inoculation with HIV-2287: implications for human transmission <i>Herz</i>		11214	
210	Class I MHC Polymorphism and Mother-to-Child HIV-1 Transmission in Kenya <i>Mac Donald</i>		31131	
211	Co-receptor usage of HIV-1 isolates of different subtypes derived during pregnancy <i>Fenyo</i>		11167	
212	Distinctive patterns of CD8 T cell clonal dominance identified in HIV-infected children by CDR3 length analysis of T Cell Receptor (TCR) V Beta Repertoire <i>Pahwa</i>		21106	
213	The expression of CD38 and DR are markers of immune activation and disease progression in HIV+ children <i>Sirera</i>		31166	
214	Influence of maternal HIV-1 and HIV-2 on child survival in the Gambia. <i>Ota</i>		12153	
215	CCR5 genotype and HIV-1 infection in perinatally-exposed infants <i>Villalba</i>		13365	

Venue:	Hall IV			
A24	Cytokines	13:00	-	14:30
Chair 1:	Dianzani, Ferdinando			
Chair 2:	Spire, Bruno			
216	Detection of memory T cells in HIV+ individuals: Cytokine Producing Lymphocyte precursors (CPLp). <i>Smith</i>		41103	
217	Alteration of intracellular cytokine synthesis in CD4+ and CD8+ cell subsets during progression of HIV disease <i>Baraba's</i>		21171	
218	Differential effects of IL-4 on HIV-1 expression suggest a role in viral phenotypic switch and disease progression <i>Pavakis</i>		21174	
219	Impact of potent anti-HIV therapy on T helper cell homeostasis and type 1 cytokine synthesis <i>Ledru</i>		21169	
220	Production of type-1, type-2 cytokines and β chemokines in HIV+ patients: influence of HAART <i>De Luca</i>		21170	
221	Patterns of cytokine production analysed at single cell level during highly active antiretroviral therapy (HAART) <i>Souza</i>		21176	

Venue:	Hall VII			
B23	Life Beyond Treatment	13:00	-	14:30
Chair 1:	Luthy, Ruedi			
Chair 2:	Sims, Ruth			
222	Palliative care and end-of-life (developed countries) <i>Selwyn</i>			
223	Care beyond treatment in developing country <i>Sharpe</i>			
224	Spiritual aspects <i>Tikkapanyo declines</i>			
225	New emotional and psychosocial issues for Patients and Providers in the era of HAART <i>Jacoby Klein</i>			
226	Legal aspects (living wills, return to work, et al.) <i>Hubner</i>			

Venue:	Arena			
B24	Antiretroviral Resistance	13:00	-	14:30
Chair 1:	Von Schoessler, Filippo			
Chair 2:	Johnson, Victoria A			
227	Review of Lago Maggiore resistance meeting (30 min) <i>Mellors</i>			
228	Frequency of transmission of drug-resistant variants in individuals with primary HIV-1 infection <i>Yerly</i>		32280	
229	HIV genotypic predictors of antiviral response to squinavir (SQV)/ ritonavir (RTV) therapy in patients who have failed prior protease inhibitors (PI's): A clinical cohort study <i>Zolopa</i>		32287	
230	Patterns of phenotypic and genotypic cross-resistance among protease inhibitors in over 1,000 clinical HIV-1 isolates <i>Hertogs</i>		42195	
231	Phenotypic HIV resistance in vitro correlates with viral load response to abacavir (1592, ABC) in vivo <i>Lanier</i>		32289	
232	Correlation of phenotypic resistance and clinical efficacy of abacavir in a phase III paediatric study <i>Danehower</i>		32283	
233	Detection of genotypic drug resistance to antiviral nucleoside inhibitors in short-time pre-treated and drug-naive HIV-1 infected patients as predictor of treatment failure in high acting antiretroviral therapy (HAART) <i>Masuhr</i>		32282	

Venue:	Hall V			
C24	Interventions for Vulnerable Women	13:00	-	14:30
Chair 1:	Quintos, Malu			
Chair 2:	Hunter, Joyce			
234	Women's health promotion - STD/AIDS prevention and control: integration of activities <i>Rivero Pupo</i>		23451	

Oral Sessions Programme

Tuesday, June 30

235	Setting the stage for a family intervention: results from focus group studies of Puerto Rican mothers and adolescent daughters <i>Nina-Estrella</i>	13404
236	Sexual coercion and HIV risk perception in Rural Uganda <i>Paxton</i>	23351
237	Working with women whose male partners are homosexually active <i>Lubowitz</i>	43256
238	Reducing harm: the effects of childhood abuse on negotiating HIV risk reduction <i>Sterk</i>	33382
239	Outcomes of a community-level HIV prevention intervention for women <i>Sikkema</i>	43228

Venue: Hall VI
C25 Migration and HIV 13:00 - 14:30
Chair 1: Shouket, Ali
Chair 2: Fleury, François

240	A Critical assessment of HIV/ AIDS prevention interventions for people on the move in Sub-Saharan Africa <i>Painter</i>	34103
241	HIV prevention in complex emergency countries <i>Sow</i>	13582
242	Mobile AIDS booths (MABS) - a novel intervention for migrating labour and their families <i>Kutikuppala</i>	23343
243	Border crossing HIV/AIDS prevention in different European states - a comparison <i>Kraus</i>	44308
244	Implications of complex emergencies, uprooting and forced migration on risk of HIV/AIDS : the case of Bosnia and Herzegovina <i>Carballo</i>	14139
245	AIDS prevention among migrant sex workers in Geneva <i>Piori</i>	43379

Venue: Satellite 2000
C26 Post-Exposure Prophylaxis 13:00 - 14:30
Chair 1: Bouvet, Elisabeth
Chair 2: Gayle, Helene D

246	Tolerability of antiretroviral agents used by health-care workers (HCWs) as post-exposure prophylaxis (PEP) for occupational exposures to HIV <i>Panlilio</i>	33171
247	Post-exposure prophylaxis for occupational and sexual exposures to HIV: experience in a London Hospital <i>Easter Brook</i>	33176
248	French physicians' experiences and attitudes about non occupational postexposure prophylaxis (PEP) <i>Laporte</i>	33192
249	Post-exposure prophylaxis following high risk sexual or injection drug use: A model feasibility program <i>Kahn</i>	33172
250	Post-sexual exposure prophylaxis (PSEP) with HAART after sexual assault <i>Opio</i>	33174
251	Post exposure prophylaxis: community controversies in San Francisco <i>Kegebein</i>	33179

Venue: Hall I
D23 Evaluation Methodology 13:00 - 14:30
Chair 1: Ankrah, Maxine
Chair 2: Wilkinson, David

252	Cochrane collaborative review group on HIV infection and AIDS: systematic reviews of HIV and AIDS prevention and treatment <i>Rutherford</i>	34356
253	A meta-analysis of the impact of HIV risk reduction interventions on safer sex behaviours of drug users <i>Semaan</i>	14250
254	A review of HIV interventions with adult heterosexually active men <i>Exner</i>	44303
256	Improving HIV/AIDS prevention interventions through program evaluation at the community level <i>Somlai</i>	44302

257	Does measured behaviour change reflect change in STD/HIV risk? <i>Peterman</i>	14252
258	Methodologic issues in outcome measures of HIV prevention research: behaviours of serodiscordant heterosexual couples <i>Huszli</i>	24169
259	Time-ordered indicators: useful and efficient tools for steering the national HIV-prevention campaign in Germany <i>Mueller</i>	33443

Venue: Hall II
D24 Coping Strategies: Individuals, Families and Organisations 13:00 - 14:30
Chair 1: Grimshaw, Jonathan
Chair 2: Musungu, Mary Jane

260	Support for patients with HIV/AIDS by training their families in integral home care (Mexico) <i>Palma Guzman</i>	24257
261	Prevention of stresses in families of HIV-infected patient to provide teaching of HIV-infected people and their families to manage stresses <i>Pidlisna</i>	33266
262	Sex after diagnosis: what support services can be provided <i>Tienudom</i>	24256
263	HIV/AIDS and employment creation <i>Nyakutombwa</i>	43159
264	Community-based home care and women's empowerment <i>Weinreich</i>	34102

Venue: Hall III
A25 Viral and T Cell Dynamics 15:00 - 17:00
Chair 1: De Wolf, Frank
Chair 2: Sheppard, Haynes W

265	Viral dynamics in HIV infected patients: correlation with host-specific factors and virological failure <i>Wu</i>	11154
266	Slow proviral DNA reduction in patients on triple drug therapy and rapid viral rebound upon stopping therapy <i>Harrigan</i>	11152
267	Modelling the sources for persistent HIV load in patients receiving HAART-evidence for a drug sanctuary compartment <i>Neumann</i>	11153
268	Increased turnover of both CD4 and CD8 T-cells in HIV-1 infection until end stage disease <i>Sachsenberg</i>	21108
269	Dynamic changes in naive and activated T cells in blood and lymph nodes in patients receiving highly active antiretroviral therapy (HAART) <i>Gray</i>	21112
270	Limited CD4+ T cell renewal as a mechanism for CD4 lymphocyte depletion in HIV-1 infection <i>Fleury</i>	21103
271	Telomere length and telomerase analysis in blood and lymphnodes provide no evidence for increased CD4+T-cell production in HIV-1 infection <i>Wolthers</i>	31168
272	Immune reconstitution of HIV discordant monozygotic twins: insight into T cell dynamics <i>Tsoukas</i>	22411

Venue: Hall IV
A26 HIV Pathogenesis 15:00 - 17:00
Chair 1: Miedema, Frank
Chair 2: Bentwich, Zvi

273	Latent viral reservoirs in patients on highly active antiretroviral therapy: implications for virus eradication <i>Finzi</i>	11150
274	Indirect mechanism of bystander cell death of CD8 T cells induced by CD4 crosslinking (XL) of CD4 T cells <i>Pahwa</i>	21159
275	Macrophages-mediated cd8+ T cell killing via cxcr4 /env interactions during HIV infection. <i>Herbein</i>	21164
276	Control of HIV-1 proliferation and pathogenesis with host factors in the hu-PBL-SCID mouse system <i>Tanaka</i>	21102

277	HIV-1 subtypes differ in time to AIDS <i>Kanki</i>	21101
278	Mechanisms of HIV transmission through epithelial cell barriers <i>Dezzutti</i>	32124
279	Seminal cell-associated viral transcriptional activity and the level of seminal B chemokines in the shedding of HIV-1 in semen <i>Gupta</i>	11151
280	Influence of interleukin-15 on apoptosis and proliferation of T lymphocytes of HIV-infected individuals: Comparison with interleukins-2 and -12 <i>Naora</i>	21162

Venue: Hall VII
B25 Adherence to Antiretroviral Therapy 15:00 - 17:00
Chair 1: Broekhuizen, Arjen
Chair 2: Kazatchkine, Michael

281	Overview <i>Chesney</i>	
282	Adherence considerations in primary care, monitoring <i>Workman</i>	
283	Various HIV communities, communication, future <i>Woodward</i>	
284	Living with the regimen <i>Ward</i>	
285	Compliance Issues in Developing Country Cultures <i>Sikipa</i>	

Venue: Arena
B26 ART II: Clinical Trials 15:00 - 17:00
Chair 1: Gazzard, Brian G
Chair 2: Hollander, Lital

286	Combination abacavir (1592, ABC)/amprenavir (141W94) therapy in HIV-1 infected antiretroviral naive subjects with CD4+ counts >400 cells/mul and viral loads >5000 copies/ml. <i>Bart</i>	12204
287	Hydroxyurea in combination regimens for the treatment of antiretroviral naive, HIV-infected adults <i>Federici</i>	12235
288	Salvage of multi-drug resistant HIV infection with D4T/3TC/hydroxyurea <i>Miles</i>	12205
289	Assessment of viral load and CD4/CD8 ratio in blood and lymph nodes in patients treated with d4T, ddI + hydroxyurea (HU) <i>Yerly</i>	41142
290	Study of protease inhibitor combination in Europe (SPICE): saquinavir soft gelatin capsule (SQV-SGC) plus nelfinavir (NFV) in HIV-infected individuals <i>Moyle</i>	12222
291	Treatment of rhonavir (RTV)/Isaquinavir (SQV) versus RTV/SQV/stavudine(d4T) (The Prometheus Study): preliminary results <i>Gisolf</i>	12274
292	Long-term evaluation of saquinavir-soft-gel-capsule or indinavir as part of combination triple therapy (CHEESE Study) <i>Boucher</i>	12267
293	The safety, tolerance, pharmacokinetics, and efficacy of PNU-140690, a new nonpeptidic HIV protease inhibitor, in a phase III study	41176

Venue: Hall V
C27 Vaccines: Overcoming Obstacles to Human Trials 15:00 - 17:00
Chair 1: Esparza, Jose
Chair 2: Berkley, Seth

294	Opening statement <i>Esparza</i>	
295	Overview of trials underway and planned <i>Heilman</i>	
296	Ethics of vaccine research and development <i>Macklin</i>	
297	Trials in developing countries <i>Bhamarapravati</i>	
298	Community Involvement and mobilisation <i>Mussauer de Lima</i>	
299	The role of industry <i>Bertrand</i>	
300	The economics of AIDS vaccines and prevention <i>Feacham</i>	

301	Closing statement <i>Berkley</i>	
302	Questions from the floor	

Venue: Hall VI
C28 Mobile Populations and HIV: Vulnerability, Risk and Human Rights 15:00 - 17:00
Chair 1: Haour-Knipe, Mary
Chair 2: Tezzo, Robert

303	HIV and human mobility: an epidemiological overview <i>Adrien</i>	
304	War, Refugees and HIV <i>Obaso</i>	
305	Mobile populations and risk situations in Mexico and Central America <i>Bronfman</i>	
306	Mobile populations and risk situations in Southeast Asia <i>Fernandez</i>	
307	Labour migration and HIV epidemics in Africa <i>Decosas</i>	
308	Human rights issues <i>Gilmore</i>	
309	Third World Immigrant Rights Struggles or AIDS Justice in Fortress Europe <i>Sadki</i>	

Venue: Hall I
D25 Mother-to-Child HIV Transmission: Infant Feeding 15:00 - 17:00
Chair 1: Lhotska, Ludmila
Chair 2: Oyuge, Catherine

317	Discussant <i>Peckham</i>	
310	Breastfeeding programmes and HIV questions <i>Savage-King</i>	
312	Psychosocial aspects of breastfeeding <i>Sherr</i>	
313	Breast feeding in the HIV/AIDS Era in Zimbabwe <i>Maposhere</i>	44266
314	Attitudes and behaviour of HIV infected women on infant feeding <i>Grey</i>	
315	Strategies for preserving breastfeeding <i>Bassett</i>	
316	Breast or bottle? A cost-effectiveness evaluation of formula feeding for the prevention of postnatal transmission of HIV in an urban South African setting <i>Söderlund</i>	24124
311	ICW Reproductive Project <i>Francis</i>	

Venue: Hall II
D26 Funding and Policy: Closing the Gap 15:00 - 17:00
Chair 1: Hauser, Dominique
Chair 2: Mahathir, Marina

	The Role of Bilaterals in National HIV/AIDS Efforts <i>Rock</i>	
318	Health reform and funding by international organisations and/or bilateral agreements <i>Ngom</i>	
319	Funding priorities for HIV/AIDS in economic crisis (i.e. faced with budget cuts) <i>Pothisiri, Pakdee</i>	
320	Funding a national policy against the HIV/AIDS epidemic <i>Yin Dakui</i>	
321	The fund for therapeutic solidarity <i>Kouchner</i>	
322	Economics, demographic, policy justification for why government needs to be involved in AIDS and some comments on role of international funding <i>Madavo</i>	
323	Discussant <i>Mann</i>	

Oral Sessions Programme

Wednesday, July 1

Venue:	Arena			
PL3	Plenary: Care and Treatment in 1998	9:00	-	10:30
Chair 1:	Coll-Seck, Awa Marie			
Chair 2:	Gonsalvez, Gregg			
324	State-of-the-art: antiretroviral treatment in 1998 <i>Montaner</i>			
325	From scientific proof of efficacy to effectiveness in the real world <i>El-Sadr</i>			
326	From scientific proof of efficacy to effectiveness in the real world <i>Whittaker</i>			
327	Access: from basic care to state-of-the-art <i>Beloqui</i>			

Venue:	Hall IV			
A31	Humoral Immunity	11:00	-	12:30
Chair 1:	Zolla-Pazner, Susan B.			
Chair 2:	Hardy, Gregory			
328	Humoral immunity <i>Zolla-Pazner</i>			
329	HIV-1 specific mucosal IgA in a cohort of HIV-1 resistant Kenyan prostitutes <i>Kaul</i>		31101	
330	Study of the impact of neutralising antibodies on the course of established infection with HIV-1 primary isolates in the hu-PBL-SCID mouse model <i>Poignard</i>		31103	
331	The antibody response in HIV-1 infection is directed against viral debris rather than virions <i>Parren</i>		31104	
332	Role of glycosylation in HIV Infection <i>Graziosi</i>		21131	

Venue:	Hall III			
B31	Clinical and Virologic Manifestation of HIV Infection	11:00	-	12:30
Chair 1:	Eron, Joe			
Chair 2:	Soares Serra, Marcio			
333	Primary HIV-1 infection: Clinical manifestations among women in Mombasa, Kenya <i>Lavreys</i>		12186	
334	Complete HIV pol sequence in plasma and genital tract of women: Genital reservoir and differential drug resistance <i>Fang</i>		32279	
335	Repertoire of chemokine receptor expression in the female genital tract: Progesterone increases CCR5, CXCR4, and CCR3 expression <i>Patterson</i>		21109	
336	Alterations in body fat distribution in HIV infected men and women <i>Kotler</i>		32173	
337	Determinants of increased energy expenditure in HIV infected women <i>Grinspoon</i>		32162	
338	Immunologic function and reconstitution in HIV infected patients on highly active antiretroviral therapy (HAART) <i>Fogelman</i>		31186	

Venue:	Hall VII			
B32	Clinical Immunology in HIV-1 Infection	11:00	-	12:30
Chair 1:	Ruxrungtham, Kiat			
Chair 2:	Lazzarin, Adriano			
339	Triple combination therapy and change in peripheral blood T-cell subset composition during asymptomatic HIV infection <i>Opravil</i>		41178	
340	Immune restoration disease after treatment of immunodeficient HIV infected patients with potent anti-retroviral therapy <i>French</i>		22323	
341	Extended benefit of protease inhibitor-containing combination therapy through a dissociated viremia-CD4 T cell response <i>Kaufmann</i>		12101	
342	Discrepant immunologic and virologic responses in HIV infected patients receiving triple combination therapy <i>Piketly</i>		32259	
343	IL2 in HIV patients: A randomised trial comparing SC, PEG, CIV IL2 with AZT+ddl <i>Levy</i>		41129	

344	Long-term follow-up of an early HIV infected cohort receiving intermittent outpatient treatment with subcutaneous interleukin-2 (sclL-2) <i>Davey Jr.</i>	41230
345	Changes in lymphocyte subsets with interleukin-2 therapy in patients with advanced HIV disease on highly active antiretroviral therapy (HAART) <i>Berger</i>	22412
346	In vivo persistence of genetically modified, HIV-I-specific syngeneic lymphocytes in HIV- 1-discordant identical twins <i>Walker</i>	42322

Venue:	Arena			
B33	Current Limits and Future of ART	11:00	-	12:30
Chair 1:	Van Praag, Eric			
Chair 2:	Ndoye, Ibrahim			
347	Barriers to therapeutic effectiveness of ART <i>Brabazon</i>			
348	Issues in clinical management in middle income settings <i>Cahn</i>			
349	Implications of ART use in resource-poor settings <i>Katabira</i>			
350	The future of HIV therapy <i>Kuritzkes</i>			

Venue:	Hall V			
C31	Forecasting and Determinants	11:00	-	12:30
Chair 1:	Gill, Noel			
Chair 2:	Horton, Muerig			
351	Forecasting the global pandemic: use and misuse of data <i>Brown</i>			
352	Epidemic determinants and dynamics in Africa <i>Awusabo-Asare</i>			
353	Concepts and models: sexual networks and population groups <i>Rothenberg</i>			
354	Cost and impact of interventions on epidemic dynamics <i>Watts</i>			

Venue:	Hall VI			
C32	Local Policies, National Issues, Global Impact	11:00	-	12:30
Chair 1:	Prasad, Rao			
Chair 2:	Borromeo, Elena			
355	HIV/AIDS policy in Brazil <i>Parker</i>	43560		
356	Setting performance standards for a national HIV prevention program <i>Holtgrave</i>	43500		
357	A public health approach to move HIV prevention research to practice <i>Sogolow, Ellen</i>	43218		
358	Medical supply for HIV/AIDS in developing countries: Thailand experience <i>Kunanusont</i>	43506		
359	Enhancing training capacities through regional military networking in countries of Eastern and Southern Africa <i>Putra</i>	43391		
360	Integrating AIDS prevention into family planning program in southern Yunnan, China <i>Wu</i>	13403		

Venue:	Satellite 2000			
C33	Recent Diffusion of Drug Injecting: Identification and Response	11:00	-	12:30
Chair 1:	Rana, Sujata			
Chair 2:	Strathdee, Stefanie			
361	Diffusion of injecting drug use in transitional societies: Russian Federation and newly independent states <i>Khodakevich</i>			
362	Spread of injecting drug use in South and Southeast Asia: developing Asian harm reduction network <i>Narayan</i>			
363	Community-based programmes to prevent the spread of injecting drug use <i>Kumar</i>			
364	Potential spread of injecting drug use into high vulnerability populations in West Africa <i>Adelekan</i>			
365	Rapid assessment methods and intervention development for injecting and HIV infection <i>Stimson</i>			
366	Injecting drug users' viewpoint <i>Madden</i>			

Oral Sessions Programme

Wednesday, July 1

Venue:	Hall I			
D31	Panel: Approaches to Women Centred Prevention	11:00	-	12:30
Chair 1:	Mane, Purnima			
Chair 2:	Pernia, Nury			
367	Overview: issues and challenges in female-controlled prevention <i>Ankrah</i>			
368	Empowering women: meeting the challenge in a clinic setting <i>Gollub</i> Female condom: an empowering technology? <i>Kalckman</i>			
369	Responding to reality: integrating family planning and STD prevention post-ICPD <i>Jacobsen</i>			
Venue:	Hall II			
D32	Involving the Community in HIV/AIDS Prevention & Care	11:00	-	12:30
Chair 1:	Sundaraman, Sundar			
Chair 2:	Crewe, Mary			
370	Introduction <i>O'Malley</i>			
371	Strengthening the community response to the HIV epidemic in Senegal <i>Gueye</i>	34120		
372	Mobilisation of communities for social change through risk behaviour mapping <i>Nyonyo</i>	13408		
373	Community based care for people living with HIV/AIDS <i>Intermoon</i>	34140		
374	Integration of HIV/AIDS prevention and care at a community level <i>De Lima</i>	34109		
375	Discussant <i>Jana</i>			
Venue:	Hall III			
A32	Molecular Biology/New Targets	13:00	-	14:30
Chair 1:	Schinazi, Ramond F			
Chair 2:	Gurtler, Lutz. G.			
376	Inhibition of HIV-1 reverse transcription by actinomycin D (Act D): A potential approach for AIDS therapy <i>Levin</i>	11124		
377	HIV-1 Vif is an endogenous inhibitor of HIV-1 protease and peptide derivatives of Vif inhibit Gag-Pol processing and HIV-1 replication <i>Volsky</i>	11130		
378	Compensatory point mutations in the HIV gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication <i>Wainberg</i>	11126		
379	The impact of interactions between NC, viral RNA and protease of HIV-1 on infectious virion assembly <i>Erickson-Vitanen</i>	11131		
380	Quantitative molecular analysis of RNA expression of HIV infected T cell using high density oligonucleotide arrays <i>Corbell</i>	11139		
381	Molecular mechanisms of HIV-1 nuclear import: MA and Vpr are the key regulators <i>Bukrinsky</i>	11144		
Venue:	Hall VII			
A33	Viral Reservoirs	13:00	-	14:30
Chair 1:	Mboup, Soleymane			
Chair 2:	Brun-Vezinet, Françoise F.			
382	Lymphocytes and lymph nodes <i>Biberfeld</i>			
383	Dendritic cells <i>Pope</i>			
384	HIV and macrophages <i>Orenstein</i>			
Venue:	Hall IV			
B34	Clinical Care of Women with HIV	13:00	-	14:30
Chair 1:	Suwunjudee, Junsuda			
Chair 2:	Mayer, Ken			
385	Gynaecological conditions in HIV-positive women <i>Duerr</i>			
386	Treatment of HIV infection in pregnancy <i>Squires</i>			
387	Clinical care of women in the South <i>Madraa</i>			

Venue:	Arena			
B35	Adherence to ART: New Research	13:00	-	14:30
Chair 1:	Friedland, Gerald H.			
Chair 2:	Phanuphak, Praphan			
388	Strategies to optimise adherence to highly active antiretroviral treatment <i>Knobel</i>	32322		
389	Protease inhibitors (PI) in the HIV+ homeless and marginally housed(H/M): Good adherence but rarely prescribed <i>Bangsberg</i>	32406		
390	Interventions and patient outcome from a pharmacist-based HIV medication adherence referral clinic <i>Graham</i>	32323		
391	History of drug use and adherence in HIV+ persons <i>Nokes</i>	new name		32366
392	Adherence to currently prescribed antiretroviral therapies: Results from a multisite interview project <i>Nakashima</i>			32326
393	Increasing active drug users' adherence to HIV therapeutics (supported by the National Institute on Drug Abuse RO1 08014) <i>Broadhead</i>			32336
Venue:	Hall V			
C34	Bridging Session: Challenges to Implementing STD Prevention and Care	13:00	-	14:30
Chair 1:	Laga, Marie			
Chair 2:	Gerbase, Antonio			
394	From assessment to action <i>Ndowa</i>			
395	Integrating STD programmes into primary health care <i>Nunez</i>			
396	Involving non-public service providers <i>Sainath</i>			
397	Challenges in industrialised settings <i>Wasserheit</i>			
398	Strategies for asymptomatic STDs <i>Dallabetta</i>			
399	Discussant <i>Phalla</i>			
Venue:	Hall VI			
C35	Culture and Community: Men Who Have Sex With Men	13:00	-	14:30
Chair 1:	Longo, Paulo			
Chair 2:	Jayaseelan, Julian			
400	Male sex work in Mexico City <i>Liguori</i>			
401	Being Gay or what? Gender blinding among Filipino commercial sex workers and its implications on HIV/AIDS transmission <i>Patino</i>	14233		
402	Responding to the needs of Maori gay men and transsexuals who live in Sydney <i>Aspin</i>	14220		
403	"HIV intervention among Chinese MSM in Hong Kong's ""gay saunas"" <i>Smith</i>	43316		
404	Human rights advocacy: Ensuring HIV/AIDS prevention among transvestite sex workers and other gay men in Guatemala <i>Mayorga</i>	44146		
405	Holistic workshops. Prevention of sexual transmission diseases (STD) and HIV/AIDS in vulnerable populations: Men that have sex with men <i>Gauthier</i>	43277		
Venue:	Satellite 2000			
C36	Harm Reduction Programmes for IDUs	13:00	-	14:30
Chair 1:	O'Hare, Pat			
Chair 2:	Sititrai, Werasit			
406	Needle exchange-based health services as a comprehensive community prevention program <i>Allice</i>	43227		
407	HIV/AIDS prevention activity among intravenous opioids users in Klaipeda (Lithuania) <i>Slavickis</i>	23220		
408	Harm reduction and community mobilisation with IDUs on Bangladeshi/Indian border <i>Kabita</i>	33386		
409	The impact results of a peer-driven intervention to combat HIV among drug injectors <i>Broadhead</i>	33335		

Oral Sessions Programme

Wednesday, July 1

410	A simple method for process evaluation of needle- and-syringe-exchange programs: Results of pilot testing in Poland, 1997 <i>Alcapes</i>	23178
411	Implementing a harm reduction program (HRP) in the complex environment of Rio de Janeiro City <i>Telles</i>	33390

Venue: Hall I
D33 Stigma and Discrimination 13:00 - 14:30
Chair 1: Lawson, Philippa.
Chair 2: Toh, Paul

412	Stigma associated with trial participation <i>MacQueen</i>	
413	Predictors for not currently receiving protease inhibitor therapy: Results from a multisite interview project <i>Nakashima</i>	42282
414	Circumstances of diagnosis of HIV infection in Belo Horizonte, Brazil <i>Campos</i>	42228
415	Legal provision for clients with HIV <i>Sherr</i>	44116
416	AIDS stigma and HIV-related beliefs in the United States: Results from a national telephone survey <i>Herek</i>	44173
417	AIDS stigma: A persistent social phenomenon in Mwanza, Tanzania <i>Nnko</i>	34159

Venue: Hall II
D34 Taking care of the Future: Support for Orphans 13:00 - 14:30
Chair 1: Odhiambo, Dorothy Achieng
Chair 2: Kathuria, Ravinder

418	Evaluation criteria of foster care of HIV affected children <i>Oletto</i>	34238
419	AIDS orphans in direct support <i>Alibuni Dropia</i>	13373
420	Children of the cities - A situation analysis of urban orphans due to AIDS in Bulawayo <i>Mithombeni</i>	34174
421	Preventing displacement of children orphaned by AIDS in Brazil <i>Fontes</i>	24220
422	AIDS orphans in Nairobi slums <i>Thumi</i>	24219
423	What it means for the future (social cost) <i>Hunter, Susan</i>	

Venue: Hall III
A34 Immune Responsiveness and Reconstitution 15:00 - 17:00
Chair 1: Biberfeld, Gunnel
Chair 2: Capobianchi, Maria

424	How HIV defeats the immune system <i>Sékaly</i>	
425	Immune events in early HIV infection <i>Walker</i>	
426	Immune responses and reconstitution <i>Aufran</i>	
427	Cytokines <i>Lane</i>	

Venue: Hall IV
A35 Molecular Epidemiology 15:00 - 17:00
Chair 1: McCutchan, Francine E
Chair 2: Nkengasong, John N.

428	Overview of molecular epidemiology <i>McCutchan</i>	
430	Molecular epidemiology of HIV-1 genetic subtypes in West and Central Africa <i>Peeters</i>	11163
431	The molecular epidemiology of HIV-1 in Uganda <i>Downing</i>	13109
434	HIV-1 subtypes circulating in Sao Paulo, Brazil <i>Brigido</i>	13162
436	Correlation between risk factors for HIV infection in Russia and HIV-1 subtypes isolated in Russia in 1994-1997 <i>Ladnaia</i>	13206

429	Genetic recombination of HIV-1 strains identified in China <i>Shao</i>	11179
432	HIV-1 group M and HIV-1 group O co-infections in Cameroon <i>Zekeng</i>	11187
435	Inter-subtype recombinant strains of HIV-1 are frequently found among new full length sequences <i>Laukkanen</i>	11170
433	Variability of HIV-2 from patients living in France <i>Simon</i>	11205

Venue: Hall VII
B36 Effects and Use of Antiretroviral Therapy 15:00 - 17:00
Chair 1: Mouton, Yves
Chair 2: Badaro, Roberto

437	Regional survival differences across Europe in HIV positive patients reflect differences in antiretroviral treatment Data from the EuroSIDA Study Group <i>Chiesi</i>		12272
438	Changes in use of antiretroviral therapy in regions of Europe over time: The EuroSIDA Study <i>Lundgren</i>		
439	Preliminary comparison of outcome in patients starting either ritonavir (R), indinavir or saquinavir (S) in 1749 patients from the EuroSIDA Study <i>Kirk</i>		
440	Clinical progression and adverse events in a cohort of HIV infected patients with advanced immunodeficiency started on protease inhibitors (PI) in March 1996 <i>Chene</i>		12266
441	Mortality and health care costs for 6,297 AIDS patients in California before and after protease inhibitors <i>Sun</i>	new name	12264
442	Changes in HIV/AIDS patterns of care and estimated costs at an urban medical centre during the era of HAART <i>Rawlings</i>		42430
443	Inversion of inpatient/outpatient HIV service utilisation: Impact of improved therapies, clinician education and case management in the US Department of Veteran Affairs <i>Deyton</i>	new name	42429
444	One world, one hope: The cost of making antiretroviral therapy available to all nations <i>Hogg</i>		42283
445	Assessment of eligibility for antiretroviral therapy among HIV-infected patients attending selected outpatient clinics in Abidjan, Côte d'Ivoire <i>Djomand</i>		42291
446	Why is highly active antiretroviral therapy (HAART) not prescribed or why is it discontinued - A prospective analysis in the Swiss HIV cohort study (SHCS) <i>Battegay</i>		32335

Venue: Arena
B37 Tuberculosis: Prevention and Management 15:00 - 17:00
Chair 1: Kibuga, Daniel
Chair 2: Nunn, Paul

447	A randomised trial of rifampin/pyrazinamide for 2 months vs. INH for 12 months in HIV+, tuberculin+ adults (CPCRA004/ACTG177/CDC/PAHO) <i>Chaisson</i>		22126
448	Adherence and compliance in tuberculosis preventive therapy trial at the JCRC in Uganda <i>Mulindwa</i>		22129
449	Feasibility of preventive therapy of tuberculosis for HIV infected subjects - GISTA study <i>Ippolito</i>		13261
450	Cost-effectiveness of isoniazid preventive therapy for HIV infected people in sub-Saharan Africa <i>Sacks</i>		13278
451	Isoniazid prophylaxis for tuberculosis in HIV infection: A meta-analysis of randomised controlled trials <i>Bucher</i>		22124
452	Increasing burden of tuberculosis and high rate of drug resistance in an HIV epicentre in Northern Thailand, 1989-1997 <i>Supawitkul</i>		22131
453	How likely are TB patients to be accurately diagnosed in urban health centres in Lusaka, Zambia? <i>Godfrey-Faussett</i>		22154
454	Ethambutol (EMB) in the continuation phase of tuberculosis (TB) treatment in HIV-1 infected Ugandan adults <i>Okwera</i>		22140

Oral Sessions Programme

Wednesday, July 1

Venue: Satellite Hall 2000
B38 **The 1998 Treatment Guidelines IAS/USA**
Chairs: to be announced

Venue: Hall V
C37 **Mother-to-Child HIV Transmission: 15:00 - 17:00**
New findings
Chair 1: Nduati, Ruth Wanjitzu
Chair 2: Webb, Ruth

456	Late postnatal mother-to-child transmission (LPT) of HIV-1: International multicentre pooled analysis <i>Leroy</i>	23266
457	HIV infection due to breastfeeding in a cohort of babies not infected at enrolment <i>Taha</i>	23270
458	Control of maternal HIV-1 disease during pregnancy <i>Beckerman</i>	23273
459	Missed opportunities to reduce perinatal HIV transmission: Maternal and neonatal zidovudine (ZDV) use in Los Angeles county (LAC) <i>Frederick</i>	12151
460	Health care providers' awareness of the ACTG 076 findings and their adherence to government guidelines to reduce perinatal transmission of HIV <i>Hertz</i>	42210
461	Association between placental malaria infection and increased risk of mother-to-infant transmission of HIV-1 in western Kenya <i>Siekete</i>	23268
462	Risk factors for perinatal HIV transmission in women/infants receiving standard zidovudine (ZDV) prophylaxis <i>Lambert</i>	23265
463	Combination therapy with nevirapine, zidovudine and a second nucleoside analogue during pregnancy <i>Kramer</i>	12152

Venue: Hall VI
C38 **Male and Female Condoms 15:00 - 17:00**
Chair 1: Spencer, Brenda
Chair 2: Islam, Monir

464	The condom user: ensuring the safety and acceptability of the product <i>Gerofi</i>	
465	The would-be condom user: making the right product available at the right time <i>Friel</i>	
466	Free condoms/sold condoms: Which is actually used? Lessons from the field in a remote district of Northern Uganda <i>Homsy</i>	14263
467	Analysis of unit costs in 23 condom social marketing programs 1990-1996 <i>Stallworthy</i>	44240
468	Challenges to female condom integration into condom programming <i>Sakondhavat</i>	
469	The promise of female-controlled methods: Zimbabwe experience of social marketing of female condom <i>Tsapotsa</i>	
470	New perspectives for condoms <i>McIntyre</i>	

Venue: Hall I
D35 **Bridging Session: Ethics and Science 15:00 - 17:00**
Chair 1: Bayer, Ronald
Chair 2: Gilmore, Norbert

471	Additional unethical aspects of vertical transmission studies in developing countries <i>Luire</i>	44123
472	Reply <i>Coovadia</i>	
473	Developing policies on HIV/AIDS and pregnancy that respect law, ethics and human rights <i>Stoltz</i>	44101
474	Ethics in HIV/AIDS research in Kenya. The cases of Immunex, Kemron, Pearl Omega and Polyatomic Capheresis (WDDS treatment) <i>Rachier</i>	44140
475	Ethical vs. moral duties when HIV/AIDS clinical trials end <i>Valdespino Gomez</i>	44126

476 Providing care, support and treatment to HIV-positive injection drug users: Legal and ethical issues
Oscapella 44135

Venue: Hall II
D36 **Resource Allocation: How to Get the Most Out of Limited Resources? 15:00 - 17:00**

Chair 1: Poolcharoen, Wiputh
Chair 2: Msuya, Wences

477	Costing HIV using an observation database <i>Mc Murchy</i>	24127
478	The impact of HIV/AIDS on the health sector in Uganda <i>Jjemba</i>	43497
479	The cost-effectiveness of prophylaxis for mycobacterium avium complex in AIDS <i>Freedberg</i>	44238
480	Costing HIV/AIDS: The Canadian HIV/AIDS economic research initiative <i>Dunbrack</i>	24122
481	The affordability of antiretroviral therapy in developing countries: What policymakers need to know <i>Forsythe</i>	44245
482	Expansion of U.S. Medicaid system to cover HIV drugs will prevent thousands of deaths and AIDS diagnoses, and is affordable <i>Kahn</i>	44241
483	Home-based nursing care: The cost effective way <i>Scheepers</i>	22466
484	Implicit valuation of a blood exclusion decision <i>Kaplan</i>	44244

Notes

Venue: PL4	Hall I Plenary Session: Consequences of an Evolving Epidemic	9:00	-	10:30
Chair 1:	Merson, Michael H.			
Chair 2:	Pellegrini, Heydee			

485	From personal to global survival <i>Hourcade Belloque</i>			
486	From personal to global survival <i>Maina</i>			
487	Priorities for public funds: crises in national leadership? <i>Ojwok</i>			
488	Priorities for public funds: crises in national leadership? <i>Mahathir</i>			
489	Human rights: consequences for the epidemic HIV <i>Cameron</i>			

Venue: PPL4	Arena Plenary: Biomedical Advances in HIV Research	9:00	-	10:30
Chair 1:	Waldvogel, F.			
Chair 2:	Nichols, Kim			

490	How viruses cause immunosuppression <i>Zinkernagel</i>			
491	The significance of virus subtypes for epidemiology and pathogenesis <i>Goudsmit</i>			
492	How HIV functions, multiples and causes disease: possible new approaches to therapy <i>Gallo</i>			

Venue: A41	Hall VII Vaccine Trials in Humans	11:00	-	12:30
Chair 1:	Churdboonchart, Vina			
Chair 2:	Kozlov, Andrei			

493	Vaccine Induction Immune Response <i>Corey</i>			
494	Induction of immune responses <i>Weinhold</i>			
495	CD8+CTL induced in AIDS vaccine evaluation group phase I trials using canarypox vectors (ALVAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost <i>Evans</i>		21192	
496	A phase I trial of vaccinia-env/gag/pol (TBC-3B) given by alternative routes, boosted with rgp120 <i>Keefer</i>		21199	
497	HIV-1 cross-clade lymphoproliferative responses following immunisation with recombinant Gp120 SF2 <i>Chuenchitra</i>		21201	
498	NIAID funding opportunities for AIDS vaccine research: new strategy and programs <i>Bende</i>			

Venue: B41	Hall III Care in Special Populations	11:00	-	12:30
Chair 1:	Shearer, Robert			
Chair 2:	Mellors, Shaun			

499	Virologic response to antiretroviral therapy among HIV-infected injection drug users <i>Mannheimer</i>		32407	
500	Barriers to HIV antiretroviral therapy among injection drug users in settings with and without universal health insurance coverage <i>Celentano</i>		42285	
501	Prisons and public health: emerging issues in HIV treatment adherence <i>Frank</i>		32408	
502	Continuity of medical care and risk of incarceration in HIV+ and HIV high risk women <i>Flanigan</i>		32411	
503	Health status and co-morbidity of HIV+ and HIV-out-of-treatment injection drug users (IDUs) <i>Allice</i>		32409	
504	Pozfit, positively fit: a prospective, pilot project in community-based HIV rehabilitation services <i>Bally</i>		42400	
505	Palliative care for HIV infection in a skilled nursing facility <i>Selwyn</i>		22427	

Venue: B42	Hall IV Predictors of Response to Antiretroviral Treatment	11:00	-	12:30
Chair 1:	Mugenyi, Peter			
Chair 2:	Anderson, Jonathan			

506	HIV RNA, CD4+ cell count, and immune activation markers predict HIV-related wasting prior to AIDS in the Multicenter AIDS Cohort Study (MACS) <i>Lyles</i>		32167	
507	HIV serum RNA, CD4 cell numbers and risk for clinical endpoints in a case-cohort study of ACTG 175 <i>Katzenstein</i>		12124	
508	"Phosphorylation rate of 3'-azidothymidine in maternal and foetal peripheral blood mononuclear cells at term" <i>Agbaria</i>		42258	
509	Zidovudine (ZDV) phosphorylation determined at intervals over 12 months in naive and antiretroviral experienced HIV+ patients <i>Back</i>		42260	
510	The rate of decline of HIV-1 RNA in plasma correlates with neftinavir concentrations in plasma <i>Hoetelmans</i>		42259	
511	Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period <i>Hoetelmans</i>		42261	
512	Saliva as a possible specimen for monitoring compliance and plasma levels in patients treated with indinavir (IDV) <i>Hugen</i>		32330	

Venue: B43	Arena HIV Infection in Children	11:00	-	12:30
Chair 1:	Osborne, Connie Mwaie			
Chair 2:				

513	Markers for diagnosis and for monitoring therapy in children <i>Ziegler</i>			
514	Clinical management in the North <i>Burchett</i>			
515	Clinical management in resource-poor setting in the South <i>Solomon</i>			
516	Palliative care for children <i>Oleske</i>			

Venue: C41	Hall V Trends and Patterns of HIV Epidemics	11:00	-	12:30
Chair 1:	Castilho, Euclides			
Chair 2:	Casabona, Jordi			

517	HIV infection in young men in Northern Thailand, 1991-1997, increasing role of injection drug use <i>Nelson</i>		43555	
518	Epidemiology of HIV-1 seroconversion among young adults in the U.S. Army, 1985-1996: current trends in an evolving epidemic <i>Renzullo</i>		13212	
519	Risk for HIV-1 seroconversion in the Ugandan people's defence forces <i>George</i>		23507	
520	Annual HIV incidence decreased among persons with sexually transmitted diseases (STD) in Italy between 1988 and 1994 <i>Sulligoi</i>		13281	
521	HIV in the Philippines: analysis of data from the national HIV sentinel surveillance system <i>Lim-Quizon</i>		43508	
522	The HIV/AIDS epidemic in Europe: changing trends and new challenges <i>Hamers</i>		13179	

Venue: C42	Hall VI STD/HIV Interaction	11:00	-	12:30
Chair 1:	Hira, Subhash			
Chair 2:	Wasserheit, Judy			

523	Overview of the STD-HIV interaction <i>Holmes</i>			
524	Population attributable risk of HIV incidence associated with STD symptoms, Rakaj Community-Based Study, Uganda <i>Wawer</i>		23372	

525	STD control for HIV prevention in the US: Is there likely to be an impact? <i>Kassler</i>	33238
526	Estimating the effect of treating sexually transmitted diseases (STDs) on HIV transmission <i>Rothenberg</i>	23369
527	Heterosexual and perinatal transmission of HIV-1: associations with bacterial vaginosis (BV) <i>Taha</i>	23347
528	A randomised trial of STD control during pregnancy in Rakai, Uganda: impact on maternal and infant health <i>Gray</i>	23276

Venue:	Satellite Hall 2000			
C43	Rapid Assessment for Intervention Development	11:00	-	12:30
Chair 1:	Stimson, Gerald V.			
Chair 2:	Mertens, Thierry E.			

529	Rapidly responding to HIV and AIDS - can social science inform community and international interventions? <i>Fitch</i>	24178
530	Mekong movements: border areas HIV/AIDS prevention project <i>Tran Minh</i>	43237
531	Situation analysis of prostitution in Bobo Dioulasso, Burkina Faso and vulnerability of the sex workers in the context of the HIV epidemic <i>Cartoux</i>	43290
532	Effectiveness of peer education and monitoring of condom use by the sex workers in brothel settings in Bangladesh for prevention of HIV <i>Begum</i>	33521
533	Peer education to reduce STD/HIV transmission in Mutare, Zimbabwe <i>Mashababe</i>	33516

Venue:	Hall I			
D41	Human Rights and Legal Challenges	11:00	-	12:30
Chair 1:	Kramer, Ian			
Chair 2:	Maluwa, Miriam			

534	Developing the human rights program for the AIDS Prevention Council in Jalisco, Mexico <i>Diaz Camarena</i>	44145
535	Training HIV positive people to document human rights violations in Asia: the APN+ Human rights initiative <i>Paxton</i>	44133
536	Access to treatment: AIDS affected population in Costa Rica wins constitutional challenge <i>Matamoros</i>	44104
537	Promoting the rights of prisoners: condoms, bleach, needles, methadone and care in prisons <i>Jurgens</i>	44191
538	A human rights approach to reducing women's vulnerability to HIV/AIDS <i>Whelan</i>	44148
539	Creation of an enabling & gender just legal environment as a prevention strategy spread of HIV/AIDS amongst women <i>Dhaliwal</i>	44164

Venue:	Hall II			
D42	Workplace: Promotion, Prevention and Protection	11:00	-	12:30
Chair 1:	Okou, Richard Constant			
Chair 2:	Pramualratana, Anthony			

540	"Peer education among factory workers in Zimbabwe: providing a sustainable HIV prevention intervention" <i>Katzenstein</i>	33514
541	AIDS, India and the trucking industry <i>Kanjilal</i>	44200
542	Protecting paradise: tourism and AIDS in the Dominican Republic <i>Forsythe</i>	44239
543	UK Coalition back to work pilot project <i>Clarkson</i>	24288
544	Sexual networking and AIDS awareness program at the workplace: the case of oil locations in Nigeria <i>Faleyimu</i>	43230
545	Grief at work: helping organisations cope with AIDS-related loss <i>Gibson</i>	24243

Venue:	Hall III			
A42	Animal Models for Vaccines Development	13:00	-	14:30
Chair 1:	Biberfeld, Gunnel			
Chair 2:	Avrett, Sam			

546	Attenuated SIV vaccines: safety and efficacy following heterologous challenge <i>Lewis</i>	11238
547	Role of b-chemokines in protective immunity against intrarectal SIVsm challenge of macaques <i>Thorstensson</i>	11239
548	Recombinant vaccine-induced protection against the highly pathogenic SIVmac251 dependence on route of challenge exposure <i>Franchini</i>	21200
549	Protective T-cell mediated immunity induced by a consecutive HIV-1 DNA and avipox vaccine regimen <i>Kent</i>	21198
550	Potent neutralisation of primary HIV-1 isolates by antisera induced upon immunisation with a recombinant protein expressing the native V1V2 domain of gp120 <i>Pinter</i>	21194
551	Multi-subtype envelope-based DNA and protein immunisation strategies for broadening immune responses to HIV-1 <i>Barnett</i>	21196

Venue:	Hall VII			
A43	Pre-Clinical Drug Development	13:00	-	14:30
Chair 1:	Smart, T.			
Chair 2:	Back, D. J.			

552	Introduction <i>Condra</i>	
553	S-1153, a new non-nucleoside reverse transcriptase inhibitor of HIV-1 <i>Fujiwara</i>	41181
554	Cellular pharmacology of the antiviral agents PMPA and PMEA in vitro and in vivo <i>Fridland</i>	41175
555	A resistance surmountable HIV protease inhibitor effective against both wild-type and new analogs of HIV-1 protease <i>Kiso</i>	41212
556	Abacavir (1592, ABC) prevents spread of HIV-1 in brain tissue of SCID mice with HIV-1 encephalitis <i>Limoges</i>	11233
557	Anti-HIV activity, biochemistry, and pharmacokinetics of beta-D-2',3'-dideoxy-2',3'-dideoxy-5-fluorocytidine (D-D4FC) <i>Schinazi</i>	41174

Venue:	Hall IV			
B44	Neurological Complications of HIV	13:00	-	14:30
Chair 1:	Cinque, Paola			
Chair 2:	Simpson, David			

558	Latest developments in neuropathogenesis <i>Vitiello</i>	
559	Animal models of HIV neuropathogenesis <i>Dormont</i>	
560	Predictive markers for HIV-associated dementia and sensory neuropathy <i>McArthur</i>	32191
561	Safety and efficacy of abacavir (abc,1592) in AIDS dementia complex (study cnab3001) <i>Brew</i>	32192
562	Progressive multifocal leukoencephalopathy (PML) treatment with cidofovir <i>Al-Shahi</i>	32193
563	Evidence for independent development of RT inhibitor (RTI) resistance patterns in cerebrospinal fluid (CSF) compartment <i>Cunningham</i>	32284
564	Stavudine stops neuro-AIDS in AZT-non-responders <i>Arendt</i>	32207

Venue:	Arena			
B45	Bridging Session: Issues in Clinical Trial Design	13:00	-	14:30
Chair 1:	Flepp, Markus			
Chair 2:	Dee, Lynda			

565	What kinds of trials <i>Collier</i>	
-----	----------------------------------------	--

Oral Sessions Programme

Thursday, July 2

566	Role of cohort studies <i>Phillips</i>			
567	Trials in developing countries <i>Phanuphak</i>			
568	The patients' perspective <i>Kreppner</i>			

Venue: C44	Hall V Transgender Issues: Living with HIV, Prevention, Identity	13:00	-	14:30
Chair 1: Chair 2:	Cabral, Camille Hows, Julian			

569	Implications of living with HIV/AIDS as a transitioning transsexual woman <i>Anderson</i>	14208		
570	HIV infection among transsexual workers from developing countries. A review of six years of activity of a reference centre in Rome <i>Spizzichino</i>	23534		
571	The HIV hormone bridge: connecting impoverished HIV+ transsexual sex workers to HIV medical care <i>Grimaldi</i>	44225		
572	The health care issues of the HIV+ and HIV-incarcerated transgendered community <i>Cozza</i>	43417		
573	The Portuguese transgender community: an unknown reality <i>Bernardo</i>	43267		
574	Mobilising transgenders for HIV prevention through cultural presentation <i>Sescon</i>	23530		

Venue: C45	Hall VI Model-Based Evaluation of HIV Prevention Programmes	13:00	-	14:30
Chair 1: Chair 2:	Galvao, Jane Kaplan, Edward			

575	Patterns of participation in mass STD treatment: model-aided evaluation of impact on HIV incidence <i>Korenromp</i>	43476		
576	Potential public health impact of offering post-exposure prophylaxis (PEP) for episodic high-risk sexual behaviour by men who have sex with men (MSM) <i>Colfax</i>	33183		
577	The effects of two years of harm reduction in Rome <i>Davoli</i>	33391		
578	Cost effectiveness of a HIV/AIDS peer education programme among commercial sex workers (CSW): results from Cameroon <i>Kumaranayake</i>	33592		
579	Interaction of vaccine effectiveness and risky behaviour <i>Blower</i>	33277		
580	HIV counselling and testing in Tanzania and Kenya is cost-effective: results from the voluntary HIV counselling and testing study <i>Sweat</i>			

Venue: C46	Satellite Hall 2000 HIV and Drug Injection: A World of Epidemics	13:00	-	14:30
Chair 1: Chair 2:	Hachatrian, Alec Sarkar, Swarup			

581	Outbreaks of HIV infections among Russian IV drug users <i>Savchenko</i>			
582	HIV/AIDS risk in non-hospitalised injection drug users in Japan <i>Sankary</i>	23183		
583	Trend of HIV incidence among drug users in an HIV epicentre in Northern Thailand, 1989-1997 <i>Supawitkul</i>	23198		
584	Decline in a very large HIV epidemic: injecting drug users in New York City, 1991-1996 <i>Des Jarlais</i>	23216		
585	HIV prevalence among female injecting drug users (IDU) in London, 1990 to 1996 <i>Judd</i>	23214		

Venue: D43	Hall I What We Are Told About AIDS: Media Response and Transformation	13:00	-	14:30
Chair 1: Chair 2:	Garrett, Laurie Makinwa, Bunmi			

586	Media impact/agreement between a NGO and a national newspaper. A successful experience of collaboration <i>Brito</i>	34219		
-----	-------------------------------------------------------------------------------------------------------------------------	-------	--	--

587	Sensitising print media to AIDS and reproductive health issues <i>Mohan</i>	33447		
-----	--------------------------------------------------------------------------------	-------	--	--

588	Developing a nation-wide public service advertising in STD syndromes <i>Cabal</i>	33450		
-----	--------------------------------------------------------------------------------------	-------	--	--

589	Using ethnic media to reach multiple language migrant communities in the Sydney region <i>McMahon</i>	33445		
-----	----------------------------------------------------------------------------------------------------------	-------	--	--

590	Assessment of Moscow press participation in HIV/AIDS prevention <i>Lioubaeva</i>	33449		
-----	-------------------------------------------------------------------------------------	-------	--	--

591	Trends of reporting on HIV/MDS and mobile groups in the print media of Bangladesh: Can the media be an ally in altering the image of AIDS? <i>Barua</i>	34215		
-----	------------------------------------------------------------------------------------------------------------------------------------------------------------	-------	--	--

Venue: D44	Hall II Mental Health and HIV	13:00	-	14:30
Chair 1: Chair 2:	Sonnenberg-Schwan, Ulrike Miller Riva			

592	Counselling strategies: they work! Results from the Voluntary HIV Counselling and Testing (VCT) Study <i>Grinstead</i>	24321		
-----	---------------------------------------------------------------------------------------------------------------------------	-------	--	--

593	Confidentiality and couple HIV counselling encourage client disclosure of serostatus and risk behaviour: results from the Voluntary HIV Counselling and Testing Study <i>Grinstead</i>	24323		
-----	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------	--	--

594	Psychosocial differences in European and African HIV-positive women <i>Bungener</i>	24150		
-----	----------------------------------------------------------------------------------------	-------	--	--

595	Psychological and neuropsychological predictors of mortality and disease progression in HIV infection <i>Catalan</i>	13345		
-----	-------------------------------------------------------------------------------------------------------------------------	-------	--	--

596	Serious mental illness among HIV-infected Medicaid patients in New Jersey <i>Crystal</i>	24222		
-----	---------------------------------------------------------------------------------------------	-------	--	--

597	The personal meanings and constructs attributed to being labelled with AIDS dementia complex <i>Ben Nissan</i>	24254		
-----	-------------------------------------------------------------------------------------------------------------------	-------	--	--

Venue: A44	Hall III Cellular Immunity	15:00	-	17:00
Chair 1: Chair 2:	Aiuti, Fernando To be announced			

598	Control of HIV replication requires virus-specific helper and CTL function and levels of CTL activity are in equilibrium with viral burden <i>Kalams</i>	31130		
-----	-------------------------------------------------------------------------------------------------------------------------------------------------------------	-------	--	--

599	HIV-specific cytotoxic T lymphocytes (CTLs) in THAI exposed uninfected (EU) female sex workers (FSWs) are directed to multiple regions of HIV-1 subtype E <i>Sriwanthana</i>	31120		
-----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------	--	--

600	HIV-1 specific cytotoxic T-lymphocyte responses in uninfected Kenyan prostitutes: behavioural and immunologic correlates <i>Kaul</i>	31123		
-----	-----------------------------------------------------------------------------------------------------------------------------------------	-------	--	--

601	Cross-clade envelope Gp160, Gag p55 and Pol specific CD8+ CTL responses early following HIV-1 clade-B infection <i>Wilson</i>	31122		
-----	----------------------------------------------------------------------------------------------------------------------------------	-------	--	--

602	Cross-Clade cytotoxic T cell response to HIV-1 proteins among HLA disparate North Americans and Thais <i>Cox</i>	new name 31128		
-----	---------------------------------------------------------------------------------------------------------------------	----------------	--	--

603	New HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte (CTL) epitopes identified in studies of Thai HIV-infected female sex workers <i>McNicholl</i>	new name 31127		
-----	-----------------------------------------------------------------------------------------------------------------------------------------------------	----------------	--	--

604	HIV-specific cytotoxic T lymphocytes (CTL) in HIV-1 infected children: CTL recognition of various HIV clades <i>Riviere</i>	31132		
-----	--------------------------------------------------------------------------------------------------------------------------------	-------	--	--

605	Increased levels of b-chemokines and antigen specific T-cell proliferation in HIV-2 exposed non-infected individuals in Guinea-Bissau <i>Andersson</i>	31133		
-----	-----------------------------------------------------------------------------------------------------------------------------------------------------------	-------	--	--

Venue: A45	Hall VI Vaccines: Animal Models and Development	15:00	-	17:00
Chair 1: Chair 2:	Kallings, Lars O. Mbidde, Edward K.			

606	Introductory overview <i>Girard</i>			
-----	----------------------------------------	--	--	--

607	New approaches to an HIV vaccine <i>Emini</i>			
-----	--------------------------------------------------	--	--	--

Oral Sessions Programme

Thursday, July 2

608 The pros and cons of live attenuated vaccines.
Towards human trials with LAV (Farthing).
Pathogenicity of multiply deleted, live attenuated
lentiviruses vaccines (Ruprecht)
Farthing Ch & Ruprecht R

Venue: Hall IV
C47 **Tuberculosis and HIV in Developing Countries** 15:00 - 17:00
Chair 1: Luo, Nkanda
Chair 2: Godfrey-Faussett, Peter

609 The impact of HIV on transmission of tuberculosis (TB) in Ugandan households
Guwatudde 13258

610 Trends of HIV-1 infection among pulmonary tuberculosis adults, 1993-1997, Kampala, Uganda
Okwera 13273

611 Increasing frequency of TB among staff in a South African hospital: impact of the HIV epidemic on supply of health care
Wilkinson 13246

612 Multiple tuberculosis episodes in HIV infected individuals: is there a need for secondary chemoprophylaxis?
Kalluvya 13277

613 The impact of HIV infection on tuberculosis control: a prospective cohort study of African patients
Sonnenberg 13259

614 Evaluating community contribution to effective tuberculosis care in high HIV prevalence populations
Maher 13276

615 Multidrug resistant TB (MRTB): study of an outbreak in HIV patients
Garcia Messina 13274

616 HIV infection and TB associated with injecting drug use and resistant MTB Bangkok, Thailand
Punnotok 13264

Venue: Hall VII
B46 **HIV-Associated Neoplasia** 15:00 - 17:00
Chair 1: Schmilovich, Andres
Chair 2: Levine, Alexandra M.

617 Effect of highly active antiretroviral treatment (HAART) in patients with AIDS-associated Kaposi's sarcoma (KS)
Santambrogio 22275

618 Topical 9-cis-retinoic acid (PanretinTM) gel as treatment of cutaneous AIDS-related Kaposi's sarcoma: interim results of an international, placebo-controlled trial (ALRT 1057-503)
Bodsworth 22277

619 North American phase 3 study (protocol 110571-31) of panretin(tm) gel (lgd1057, alrt1057) for cutaneous aids-related Kaposi's sarcoma
Friedman-Kien 22283

620 HHV-8, proliferation, apoptosis and ploidy in epidemic (aks), endemic (eks), and classical (cks) Kaposi's sarcoma (ks)
Biberfeld 22282

621 Association of vitamin A deficiency with cervical dysplasia in the women's interagency HIV study (WUIS)
French 22301

622 Case-control study of cervical cancer and HIV infection in Abidjan, Côte d'Ivoire.
Adjorlolo-Johnson 22305

623 Incidence of squamous intraepithelial lesions (SIL) in HIV-infected women
Delmas 22306

624 Comparison of the amount of HPV 16 DNA in cervicovaginal secretions of HIV-Infected and uninfected women, using quantitative competitive polymerase chain reaction (QC-PCR)
Wright 22311

Venue: Arena
B47 **Grand Rounds: Clinical Case Studies** 15:00 - 17:00
Chair 1: Telenti, Amalio
Chair 2: Chipanta, David

625 Case presentations
Telenti

626 Virologic failure
Lange

627 Treatment complications
Schooley

628 A case of HIV infection in the developing world
Wong

629 Natural history of HIV-associated disease under HAART
Havlic

Venue: Hall V
C48 **Bridging Session: Microbicides: Towards a New Paradigm** 15:00 - 17:00
Chair 1: Perriens, Joseph
Chair 2: Heise, Lori

630 Economic and marketing issues
Fransen

631 State-of-the-Art: clinical research
Rosenberg

632 Overview: possibilities for specific intervention
Wainberg

633 Case study for political advocacy: Zimbabwe
Misihairabwi

634 Discussant: trials
Ramjee

635 Discussant: consumer perspective
Tharawan

636 Discussant: gvt perspective
Birnkrant

Venue: Hall I
D45 **Implications of New Treatments at Individual and Population Level** 15:00 - 17:00
Chair 1: dos Santos Filho, Ezio T.
Chair 2: Perez, C.

637 AIDS, virtually normal now? Protease inhibitors and the end of consensus
Horton 44183

638 "Do people fail drugs, or do drugs fail people? The discourse of "adherence""
Harley 34212

639 T.H.E. (tools for health & empowerment) course: a unique disease management program
Igboko 34236

640 The impacts of combination therapies on the lives of people with HIV
Weatherburn 24260

641 Treatments, intimacy and disclosure in the sexual practice of HIV-infected adults in Austria
Bartos 23402

642 HIV/AIDS preventive attitudes and behaviour of French and Swiss gay men in the era of new treatments. A comparison of two national survey.
Adam 34107

643 HAART, attitudes, and risk behaviour among serodiscordant male couples
Remien 14136

644 New therapies for HIV and sexual risk behaviour among gay men in London, UK
Elford 23106

Venue: Hall II
D46 **Resource Mobilisation: Where Will the Money Come From?** 15:00 - 17:00
Chair 1: Mukaso-Monico, Sofia
Chair 2: Cowal, Sally

645 Sustainability beyond donor aid
Atayan 44220

646 The Global Business Council on HIV/AIDS (GBC)
Plumley 44223

647 Amounts, patterns and trends of national and international financing of the response to HIV/AIDS in developing countries, 1996-1997
Tarantola 44232

648 European funding for HIV in the developing world
Pronk

649 North American funding for HIV in the developing world
Morin

650 Funders concerned about AIDS on Philanthropic funding
di Donato

651 A unique Zululand industry joint venture response to the needs of employees with HIV/AIDS
Rogers 44221

Oral Sessions Programme

Friday, July 3

Venue:	Arena	8:30	-	10:30
	Late Breakers			
Chair:	Track A			Oral presentations
	Track B			
	Track C			
	Track D			
	Break	10:30	-	11:00

Venue:	Arena	11:00	-	13:00
	Closing Ceremony			
Chairs:	WH Lindner			
	Bernard Hirschel			
	Robin Gorna			
	Rapporteurs			
	<i>A Jay Levy</i>			
	Rapporteurs			
	<i>B Richard Horton</i>			
	Passing the Globe			
	<i>Bernard Hirschel</i>			
	<i>Robin Gorna</i>			
	<i>Hoosen Coovadia</i>			
	Rapporteurs			
	<i>C Catherine Hankins</i>			
	Rapporteurs			
	<i>D to be determined</i>			
	Rapporteurs			
	<i>Community Winstone Zulu</i>			
	Awards			
	<i>IAS Young Investigators</i>			
	<i>Mark Wainberg et al.</i>			
	Other Awards			
	Keynote speaker			
	<i>Hoosen Coovadia Chair XIIIth International AIDS Conference Durban 2000</i>			
	Video			
	<i>Durban 2000</i>			

finis

For up to date news as the Conference progresses, please visit:

aids98.ch

The Online News Service of the
12th World AIDS Conference

Bridging The Gap